Drug Discovery program
A unique effort to discover new treatments for cancer, the DDP leverages the strong biology and clinical relevance of IEO’s research in cancer with industry-competitive drug discovery experience.
DDP includes about 30 scientists (lead by Dr Mario Varasi):
- medicinal, analytical and computational chemists with industrial drug discovery experience, biochemists, cell biologists and in vivo pharmacologists operating in state-of-the-art equipped labs.
Strategic Advisory Board
DDP has a SAB encompassing International scientific and business experience and it is working in close contact with the biology at the IFOM-IEO Campus to successfully bring projects up to an IND, to ensure their development for maximum patient benefit and to exploit their potential in industrial partnerships.
Current pipeline
A biology inspired-chemistry driven effort to identify small molecules for innovative therapy against cancer
- Alterations of self-renewal in cancer stem cells (CSCs)
- P53 modulators
- Inhibitors of the Spindle Assembly Checkpoint (SAC) Kinases
- Epigenetic targets for cancer therapy
- Anti-tubulin agents
Why technology transfer?
Forthcoming Events
Join us at:
- BIO International Convention, Boston, June 18-21, 2012 - Meet us at BIO!
- BIO Japan, Pacifico Yokohama, 10-12 October, 2012
Past events
Drug discovery program
A unique effort to discover new treatments for cancer, the DDP leverages the strong biology and clinical relevance of IEO’s research in cancer with industry-competitive drug discovery experience.
